Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. director and co-founder Sheena Jonathan reported multiple sales of Natera common stock on January 23, 2026 by two trusts associated with her. Caraluna 1 Trust sold an aggregate 750 shares in several trades at weighted average prices between about $242.02 and $245.19 per share, leaving it with holdings between 21,782 and 22,372 shares after each trade. Caraluna 2 Trust sold a total of 750 shares in similar transactions at weighted average prices ranging from $242.13 to $245.39 per share, ending with 21,782 shares after the last transaction. These sales were carried out under a Rule 10b5-1 trading plan adopted on June 7, 2024. Jonathan also reports 264,078 shares held directly. The trust-held shares are for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those securities.
JPMorgan Chase & Co. reports beneficial ownership of 12,825,640 shares of Natera, Inc. common stock, representing 9.1% of the outstanding class as of 12/31/2025. JPMorgan has sole voting power over 11,614,632 shares and shared voting power over 3,670 shares, and it has sole dispositive power over 12,812,792 shares and shared dispositive power over 11,783 shares.
The filing identifies multiple JPMorgan subsidiaries involved in holding these shares, including J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and several asset management entities. JPMorgan certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Natera.
Natera, Inc. CEO and President Steven Leonard Chapman reported routine equity transactions involving company stock. On January 20, 2026, he exercised 3,386 Restricted Stock Units, each representing one share of Natera common stock, and received the same number of shares. That day he sold 71,932 shares of common stock at an average price of $234.7384 per share to cover tax withholding and remittance obligations related to RSU vesting, under a pre-set instruction intended to satisfy Rule 10b5‑1(c). On January 21, 2026, he sold an additional 1,590 shares of common stock at $235 per share, also to satisfy tax obligations tied to RSU vesting.
After these transactions, Chapman beneficially owned 219,150 shares of Natera common stock directly. The RSUs referenced vest over four years, with 25% having vested on January 20, 2023 and the remainder vesting in 12 equal quarterly installments thereafter.
Natera, Inc. CFO Michael Burkes Brophy reported multiple stock transactions tied to RSU vesting and a preset trading plan. On January 20, 2026, he sold 23,948 shares of common stock at an average price of $234.7384 per share and had 1,522 Restricted Stock Units convert into the same number of common shares at an exercise price of $0. On January 21, 2026, he sold 602 shares at $235 per share and 36,573 shares at an average price of $242.6685 per share. The filing states that certain sales were made to cover tax withholding obligations upon RSU vesting and that the reported sales were executed under a Rule 10b5-1 trading plan. Following these transactions, he directly owned 64,123 shares of Natera common stock.
Natera, Inc. co-founder and director Sheena Jonathan reported January 2026 stock transactions involving common shares and restricted stock units (RSUs). On January 20, 2026, she sold 2,981 common shares at a weighted average price of $234.7384, in a sale described as satisfying tax withholding obligations tied to RSU vesting, and 191 RSUs converted into the same number of common shares. On January 21, 2026, she reported additional sales of 93, 2,470, and 600 common shares at weighted average prices of $235, $234.1157, and $235.8183, including trades made under a Rule 10b5-1 trading plan adopted on June 7, 2024. Following these transactions, she directly held 264,078 common shares and indirectly held 22,532 common shares in each of two trusts named Caraluna 1 Trust and Caraluna 2 Trust.
Natera, Inc.’s Secretary and Chief Legal Officer Daniel Rabinowitz reported routine transactions in company stock tied to restricted stock unit (RSU) vesting. On January 20, 2026, he exercised 856 RSUs, each converting into one share of common stock, and sold 19,234 shares at $234.7384 per share to cover tax withholding and remittance obligations under a pre-set Rule 10b5-1 trading instruction. On January 21, 2026, he reported an additional tax-related sale of 438 shares at $235 per share under a similar instruction.
After these transactions, Rabinowitz directly owned 227,033 shares of Natera common stock. The RSUs referenced vest over four years, with 25% having vested on January 20, 2023 and the remaining units vesting in 12 equal quarterly installments thereafter.
Natera, Inc.January 20, 2026, he sold 23,205 shares of common stock at $234.7384 per share, leaving 144,992 shares beneficially owned directly after that transaction. On January 21, 2026, he sold an additional 293 shares at $235.00 per share, with 144,699 shares beneficially owned directly afterward.
The footnotes state that both sales were effected to satisfy tax withholding and remittance obligations arising from the vesting of restricted stock units granted on January 27, 2023 and January 28, 2022, under written instructions intended to meet the affirmative defense conditions of Rule 10b5‑1(c) under the Exchange Act.
Natera, Inc. insider John Fesko, the company’s President and Chief Business Officer, reported two sales of Natera common stock. On January 20, 2026, he sold 17,806 shares at an average price of $234.7384 per share. On January 21, 2026, he sold an additional 339 shares at $235 per share.
The filing explains that both transactions were made to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units and were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions. After these transactions, Fesko beneficially owns 177,252 shares of Natera common stock directly.
Form 144 for NTRA reports a planned insider sale of common stock. The filing covers 36,573 common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $8,589,169.05. The filing notes that 138,014,465 shares of this class were outstanding.
The shares to be sold were recently acquired from the issuer via equity awards: 35,650 shares from performance stock units on 01/14/2026 and 923 shares from restricted stock units on 01/20/2026. The notice also lists prior sales over the past three months by or for Michael Brophy, including multiple common stock transactions, some under a "10b5-1 Sales Plan," with individual trades ranging from 495 to 1,867 shares and gross proceeds such as $355,924.69 and $236,838.37.
Natera, Inc.’s chief financial officer, Brophy Michael Burkes, reported the vesting of performance-based equity. On January 14, 2026, 59,596 shares of Natera common stock were acquired at a price of $0 per share upon the certification of a performance milestone under a restricted stock unit (RSU) award originally granted on January 27, 2023. The RSUs vest in tranches based on a mix of time-based service and business performance criteria. Following this vesting event, Burkes directly beneficially owns 123,722 shares of Natera common stock.